These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

527 related items for PubMed ID: 29996929

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan.
    Imafuku S, Nakano A, Dakeshita H, Li J, Betts KA, Guerin A.
    J Dermatolog Treat; 2018 Feb; 29(1):24-31. PubMed ID: 28608740
    [Abstract] [Full Text] [Related]

  • 3. Drug Survival of Biological Therapies for Psoriasis Treatment in Germany and Associated Costs: A Retrospective Claims Database Analysis.
    Mahlich J, Alba A, Hadad LE, Leisten MK, Peitsch WK.
    Adv Ther; 2019 Jul; 36(7):1684-1699. PubMed ID: 31102203
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis.
    Feldman SR, Zhao Y, Navaratnam P, Friedman HS, Lu J, Tran MH.
    J Manag Care Spec Pharm; 2015 Mar; 21(3):201-9. PubMed ID: 25726029
    [Abstract] [Full Text] [Related]

  • 8. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
    Chastek B, Chen CI, Proudfoot C, Shinde S, Kuznik A, Wei W.
    Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
    Wu JJ, Feldman SR, Rastogi S, Menges B, Lingohr-Smith M, Lin J.
    J Dermatolog Treat; 2018 Dec; 29(8):769-774. PubMed ID: 29658383
    [Abstract] [Full Text] [Related]

  • 10. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
    Baniandrés O, Rodríguez-Soria VJ, Romero-Jiménez RM, Suárez R.
    Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Implementing therapeutic goals in maintenance treatment of psoriasis with biologics: adalimumab can be more cost-effective than infliximab or ustekinumab in real life.
    Puig L, Morales-Múnera CE.
    Eur J Dermatol; 2013 Sep; 23(3):407-8. PubMed ID: 23782978
    [No Abstract] [Full Text] [Related]

  • 15. Persistency of Biologic Therapies for Plaque Psoriasis in 2 Large Community Practices.
    Verma L, Mayba JN, Gooderham MJ, Verma A, Papp KA.
    J Cutan Med Surg; 2018 Sep; 22(1):38-43. PubMed ID: 29056080
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis.
    Wu JJ, Armstrong A, Singh R, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Arikan D, Fleischer A, Guérin A, Ganguli A.
    J Drugs Dermatol; 2018 Nov 01; 17(11):1211-1218. PubMed ID: 30500143
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ, Pelletier C, Ung B, Tian M.
    J Med Econ; 2019 Apr 01; 22(4):365-371. PubMed ID: 30652520
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.